{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:01:01Z","timestamp":1794916861721,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10067-021-05785-6","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T02:02:25Z","timestamp":1622426545000},"page":"4071-4079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis\u2013related interstitial lung diseases: a retrospective, observational cohort study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-1450","authenticated-orcid":false,"given":"Deniz Demir","family":"Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-1312","authenticated-orcid":false,"given":"Sermin","family":"Borekci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7678-3393","authenticated-orcid":false,"given":"Benan","family":"Musellim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"5785_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"5785_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0302-6","author":"M Benan","year":"2007","unstructured":"Benan M, Hande I, Gul O (2007) The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-006-0302-6","journal-title":"Clin Rheumatol"},{"key":"5785_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/1479972310393758","author":"A de Lauretis","year":"2011","unstructured":"de Lauretis A, Veeraraghavan S, Renzoni E (2011) Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. https:\/\/doi.org\/10.1177\/1479972310393758","journal-title":"Chron Respir Dis"},{"key":"5785_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200111000-00008","author":"JG Coghlan","year":"2001","unstructured":"Coghlan JG, Mukerjee D (2001) The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol. https:\/\/doi.org\/10.1097\/00002281-200111000-00008","journal-title":"Curr Opin Rheumatol"},{"key":"5785_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2014.12.005","author":"SR Schoenfeld","year":"2015","unstructured":"Schoenfeld SR, Castelino FV (2015) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. https:\/\/doi.org\/10.1016\/j.rdc.2014.12.005","journal-title":"Rheum Dis Clin North Am"},{"key":"5785_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"key":"5785_CR7","doi-asserted-by":"publisher","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al. (2006) Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa055120","DOI":"10.1056\/NEJMoa055120"},{"key":"5785_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0022-2019","author":"BF Collins","year":"2019","unstructured":"Collins BF, Raghu G (2019) Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev. https:\/\/doi.org\/10.1183\/16000617.0022-2019","journal-title":"Eur Respir Rev"},{"key":"5785_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"5785_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213","author":"G Sircar","year":"2018","unstructured":"Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P (2018) Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/key213","journal-title":"Rheumatology (Oxford)"},{"key":"5785_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.22204","journal-title":"Arthritis Rheum"},{"key":"5785_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/art.40560","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"key":"5785_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30480-1","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(19)30480-1","journal-title":"Lancet Respir Med"},{"key":"5785_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-001-0247-1","author":"PM Cardelli","year":"2002","unstructured":"Cardelli PM, Quinn M, Bukman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G (2002) Binding to CD20 by anti-B1 antibody or F(ab\u2019)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer immunol immunother. https:\/\/doi.org\/10.1007\/s00262-001-0247-1","journal-title":"Cancer immunol immunother"},{"key":"5785_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.09.002","author":"SL Bosello","year":"2015","unstructured":"Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G (2015) Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.09.002","journal-title":"Semin Arthritis Rheum"},{"key":"5785_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem357","author":"D McGonagle","year":"2008","unstructured":"McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, Thomas S (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kem357","journal-title":"Rheumatology (Oxford)"},{"key":"5785_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000584","author":"A Sari","year":"2017","unstructured":"Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, Apras Bilgen S, Ertenli I, Kiraz S, Akdogan A (2017) Rituximab experience in patients with long-standing systemic sclerosis\u2013associated interstitial lung disease: a series of 14 patients. J Clin Rheumatol. https:\/\/doi.org\/10.1097\/RHU.0000000000000584","journal-title":"J Clin Rheumatol"},{"key":"5785_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa550","author":"RP Goswami","year":"2021","unstructured":"Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P (2021) Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keaa550","journal-title":"Rheumatology (Oxford)"},{"key":"5785_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Preliminary criteria for the classi","year":"1980","unstructured":"Preliminary criteria for the classification of systemic sclerosis (scleroderma), (1980) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581\u2013590","journal-title":"Arthritis Rheum"},{"key":"5785_CR20","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.93.3.580","volume":"93","author":"DA Mahler","year":"1988","unstructured":"Mahler DA, Wells CK (1988) Evaluation of clinical methods for rating dyspnea. Chest 93:580\u2013586","journal-title":"Chest"},{"key":"5785_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.10.003","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.10.003","journal-title":"Semin Arthritis Rheum"},{"key":"5785_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep093","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kep093","journal-title":"Rheumatology (Oxford)"},{"key":"5785_CR23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC","author":"DP Tashkin","year":"2007","unstructured":"Tashkin DP, Elashoff R, Clements PJ et al (2007) 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care MED. https:\/\/doi.org\/10.1164\/rccm.200702-326OC","journal-title":"Am J Respir Crit Care MED"},{"key":"5785_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/ar2534","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and metaanalysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar2534","journal-title":"Arthritis Res Ther"},{"key":"5785_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4171-6","author":"WMT van den Hombergh","year":"2018","unstructured":"van den Hombergh WMT, Simons SO, Teesselink E, Knaapen-Hans HKA, van den Hoogen FHJ, Fransen J, Vonk MC (2018) Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-018-4171-6","journal-title":"Clin Rheumatol"},{"key":"5785_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010908.pub2","author":"H Barnes","year":"2018","unstructured":"Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN (2018) Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010908.pub2","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05785-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05785-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05785-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T22:02:04Z","timestamp":1632520924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05785-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5785"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05785-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"28 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This is a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}